June 22, 2018

The adult motor phenotype of Dravet syndrome is Associated with Mutation of the STXBP1 Gene and Responds Well to Cannabidiol Treatment

Dravet syndrome is a terrible disease generally caused by mutations of the SCN1A gene. Recently others genes such as STXBP1 have been involved in the pathogenesis of the disease. The STXBP1 mutation in patients with Dravet Syndrome may additionally causes several parkinsonian features usually attributed to carriers of the SCN1A mutation. Management continues to be difficult; that is why Cannabidiol emerged as valid option for treatment of this condition.

Related News

April 15, 2024

Study Reveals Key Mechanisms of a Rare Form of Epilepsy

This study reveals that the presence of KCNQ2 G256W variants affects both molecular and cellular aspects of KCNQ channel activity, including their ion-carrying capacity, expression, and placement within cells.

March 19, 2024

Genotype–Phenotype Associations in Individuals with SCN1A-Related Epilepsies

Understanding genotype–phenotype associations in SCN1A-related epilepsies is critical for early diagnosis and management.

February 14, 2024

Fintepla Safely Reduces Seizures in Children Younger than 2, Study Finds

Treatment with Fintepla (fenfluramine) appeared to be reasonably safe and lower seizure frequency in five children with Dravet syndrome who started on the therapy before they were two years old.